Ken Griffin Oyster Point Pharma, Inc. Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$7.95 - $11.68 $2.12 Million - $3.11 Million	-266,547 Reduced 90.03%	29,511 $329,000
Q3 2022 Nov 14, 2022	BUY	$4.41 - $8.38 $320,135 - $608,329	72,593 Added 32.49%	296,058 $1.66 Million
Q2 2022 Aug 15, 2022	BUY	$3.6 - $11.2 $423,302 - $1.32 Million	117,584 Added 111.05%	223,465 $968,000
Q1 2022 May 16, 2022	SELL	$8.58 - $17.65 $212,826 - $437,808	-24,805 Reduced 18.98%	105,881 $1.23 Million
Q4 2021 Feb 14, 2022	SELL	$10.17 - $18.96 $18,438 - $34,374	-1,813 Reduced 1.37%	130,686 $2.39 Million
Q3 2021 Nov 15, 2021	BUY	$11.67 - $18.07 $343,051 - $531,185	29,396 Added 28.51%	132,499 $1.57 Million
Q2 2021 Aug 16, 2021	SELL	$16.25 - $21.51 $2.1 Million - $2.78 Million	-129,103 Reduced 55.6%	103,103 $1.77 Million
Q1 2021 May 17, 2021	SELL	$17.92 - $25.86 $896,000 - $1.29 Million	-50,000 Reduced 17.72%	232,206 $4.25 Million
Q4 2020 Feb 16, 2021	BUY	$18.13 - $25.18 $90,650 - $125,900	5,000 Added 1.8%	282,206 $5.31 Million
Q3 2020 Nov 16, 2020	SELL	$17.83 - $29.12 $77,310 - $126,264	-4,336 Reduced 1.54%	277,206 $5.85 Million
Q2 2020 Aug 14, 2020	BUY	$27.86 - $35.93 $7.29 Million - $9.4 Million	261,668 Added 1316.63%	281,542 $8.13 Million
Q1 2020 May 15, 2020	BUY	$23.65 - $40.96 $470,020 - $814,039	19,874 New	19,874 $696,000

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.